8-K current report · filed Oct 22, 2026

MBX Biosciences, Inc. (MBX) 8-K Current Report: October 22, 2026

Item 5.02MBX overview

Short answer

MBX Biosciences, Inc. (MBX) filed an 8-K current report with the SEC on October 22, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Peter Radovich appointed independent director effective October 20, 2026, expanding the Board to eight members.

MBX Biosciences, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • Peter Radovich appointed independent director effective October 20, 2026, expanding the Board to eight members
  • Class I director term runs through the 2028 Annual Meeting, supporting near-term board continuity
  • Initial equity award: non-qualified option for 18,200 common shares
  • Additional cash compensation under MBX’s amended Non-Employee Director Compensation Policy
  • Indemnification agreement matches arrangements for existing directors, with no disclosed related-party transactions

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other MBX Biosciences, Inc. 8-K filings

Get the next MBX 8-K as it lands

Follow MBX for push alerts, or ask the research agent what this filing means.